Femasys Inc has 7 Schedule 13D or 13G filings on record since 2025-08-05. 7 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Alumni Capital LP | 9.99% | 4,773,579 | SCHEDULE 13G, 2025-09-04 | 2025-09-04 |
| Nantahala Capital Partners Limited Partnership | 9.99% | 803,038 | SCHEDULE 13D, 2026-08-17 | 2026-08-10 |
| Dauntless Investment Group, LLC | 9.9% | 4,395,996 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Rosalind Advisors, Inc. | 9.9% | 4,687,500 | SCHEDULE 13G, 2026-08-14 | 2026-08-10 |
| Chernett Jorey | 9.3% | 3,034,335 | SCHEDULE 13G/A, 2025-08-05 | 2025-06-30 |
| PharmaCyte Biotech, Inc. | 7.87% | 4,932,825 | SCHEDULE 13G, 2026-03-18 | 2026-03-17 |
| Stonepine Capital Management, LLC | 7.2% | 625,000 | SCHEDULE 13G, 2026-08-31 | 2026-08-10 |
Purpose of Transaction (Item 4)
Nantahala Capital Partners Limited Partnership
The disclosure regarding the SPA and the Purchase set forth above in Item 3 is incorporated herein by reference. The Issuer has further described the SPA, the Purchase and the Side Letter in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the "SEC") on August 14, 2026. Pursuant to a side letter (the "Side Letter") entered into by Nantahala and the Issuer on August 7, 2026, for so long as Nantahala beneficially owns at least 15% of the outstanding shares of Common Stock (which determination shall be made without regard to the Beneficial Ownership Limitation), until the tenth anniversary of the Purchase, the board of directors (the "Board") of the Issuer shall appoint a Nantahala designee as a member of the Board (and any of its committees), subject to the reasonable agreement of the Issuer and applicable qualification requirements; Nantahala shall have the right to receive certain financial information and information presented to the Board, meet with Issuer management on a quarterly basis and be informed of certain material developments and events, subject to customary confidentiality obligations; and the Issuer shall refrain from taking certain actions without Nantahala's prior written consent, including entering into certain affiliated transactions, increasing the size of the Board, making certain terminations of, or replacing, the Issuer's chief executive officer, declaring certain dividends or distributions, incurring indebtedness in …The first part of Item 4 of the SCHEDULE 13D filed 2026-08-17; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-05 | Chernett Jorey | 9.3% | SCHEDULE 13G/A |
| 2025-09-04 | Alumni Capital LP | 9.99% | SCHEDULE 13G |
| 2025-11-14 | Dauntless Investment Group, LLC | 9.9% | SCHEDULE 13G/A |
| 2026-03-18 | PharmaCyte Biotech, Inc. | 7.87% | SCHEDULE 13G |
| 2026-08-14 | Rosalind Advisors, Inc. | 9.9% | SCHEDULE 13G |
| 2026-08-17 | Nantahala Capital Partners Limited Partnership | 9.99% | SCHEDULE 13D |
| 2026-08-31 | Stonepine Capital Management, LLC | 7.2% | SCHEDULE 13G |
Femasys Inc: every filing and event
Tools for this story
Each opens in a new tab, filled in for Femasys Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.